This site is intended for health professionals only
NicOx S.A. (NYSE Euronext Paris: COX) has convened an extraordinary shareholder meeting on second call on the same agenda on Friday July 27, 2012 at 12:30 pm CET at the Mercure hotel – rue Albert Caquot – 06560 Sophia Antipolis – France.
The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de commerce, including a proxy voting form, are sent to shareholders upon written request. These documents are available to shareholders at the headquarters and on the website of the Company (www.nicox.com).
For questions on the voting procedures, a telephone line is made available to shareholders. The dial number is +33 (0)4 97 24 54 44. Shareholders may also contact the Investor Relations team by email at firstname.lastname@example.org.
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is building an international late-stage development and commercial Ophthalmology Company based around therapeutics, diagnostics and devices.
NicOx is also developing an internal portfolio of New Molecular Entities (NMEs) through the application of its proprietary nitric oxide-donating R&D platform. The Company’s pipeline includes several nitric oxide-donating NMEs for the potential treatment of ophthalmological, inflammatory and cardio-metabolic diseases, which are in development internally and with partners, who include Bausch + Lomb, Merck (known as MSD outside the United States and Canada) and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment C: Small Caps).